Key result
Carvedilol inhibits serum-induced proliferation in ~86% of human vascular smooth muscle cells.
Why the study?
The antiproliferative effects of the novel antihypertensive agent carvedilol on human vascular smooth muscle cells were examined to explore its potential against VSMC proliferation associated with hypertension and atherosclerosis.
Does carvedilol inhibit the proliferation of human vascular smooth muscle cells in vitro?
Does carvedilol inhibit the proliferation of human vascular smooth muscle cells in vitro?
Carvedilol inhibits human vascular smooth muscle cell proliferation in vitro, particularly in cells derived from restenotic lesions, though at supra-physiologic concentrations.
No takes yet. Share an insight, caveat, or question.
Does not support clinical use; leaves open whether antiproliferative effects reduce restenosis in vivo.
Patel et al. (1995) studied Vascular smooth muscle cell proliferation (n=21). Carvedilol vs. Other beta-adrenoceptor antagonists, verapamil, and amlodipine was evaluated on Inhibition of increase in cell number induced by foetal calf serum. Carvedilol inhibited foetal calf serum-induced proliferation in 86% (18 of 21) of human vascular smooth muscle cells, with 17.6% inhibition in saphenous vein and 31.4% in restenotic lesion cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: